Consumer Insights
Uncover trends and behaviors shaping consumer choices today
Procurement Insights
Optimize your sourcing strategy with key market data
Industry Stats
Stay ahead with the latest trends and market analysis.
Explore Our Diverse Range Of Offerings
From detailed reports to experts services offered in 15+
Industry Domains
Add 2 More Reports For 20% off
Report Overview
Substance use disorder remains a critical global health concern characterized by dependence on alcohol and other addictive substances that significantly affect physical, mental, and social well-being. According to World Health Organization, nearly 400 million people worldwide live with alcohol use disorders, representing the largest share of substance-related conditions. Rising prevalence among younger populations and changing substance consumption patterns continue to shape the global burden. The substance use disorder pipeline analysis by Expert Market Research highlights growing research efforts focused on developing targeted pharmacotherapies and innovative treatment strategies.
-
Major companies involved in the substance use disorder (SUD) pipeline analysis include Afasci Inc., Eli Lilly and Company, Boehringer Ingelheim, and others.
-
Leading drugs currently in the pipeline include XR-B + XR-NTX, LY3537031, and others.
-
The pipeline landscape is gaining momentum as precision neuroscience and neurocircuit-targeted therapeutics reshape addiction treatment strategies. The growing clinical focus on long-acting pharmacotherapies and relapse-prevention mechanisms is expanding innovation in candidates targeting reward pathways.
Report Coverage
The Substance Use Disorder (SUD) Pipeline Analysis Report by Expert Market Research gives comprehensive insights into substance use disorder (SUD) therapeutics currently undergoing clinical trials. It covers various aspects related to the details of each of these drugs under development for substance use disorder (SUD). The substance use disorder (SUD) report assessment includes the analysis of over 100 pipeline drugs and 50+ companies. The substance use disorder (SUD) pipeline landscape will include an analysis based on efficacy and safety measure outcomes published for the trials, including their adverse effects on patients suffering from the condition, and alignment with substance use disorder (SUD) treatment guidelines to ensure optimal care practices.
The assessment part will include a detailed analysis of each drug, drug class, clinical studies, phase type, drug type, route of administration, and ongoing product development activities related to substance use disorder (SUD).
Read more about this report - Request a Free Sample
Substance Use Disorder (SUD) Pipeline Outlook
Substance use disorder (SUD) is a chronic brain condition where a person compulsively uses substances, such as alcohol, drugs, or medications, despite harmful consequences. It occurs when repeated substance exposure alters brain chemistry, particularly the dopamine reward system, creating intense cravings, tolerance, and dependence, making voluntary control increasingly difficult over time.
Substance use disorder treatment strategies typically involve medication-assisted therapies, behavioral interventions, and long-acting pharmacotherapies such as Buprenorphine and Naltrexone to reduce cravings and withdrawal symptoms. For instance, in February 2025, the UnitedStates Food and Drug Administration approved updated labeling for Sublocade (extended-release buprenorphine injection) for moderate to severe opioid use disorder. The update introduced a rapid-initiation protocol and additional injection-site options, enabling treatment after a single buprenorphine dose and improving clinical flexibility for healthcare providers managing opioid addiction.
Substance Use Disorder (SUD) Epidemiology
Substance use disorders represent a major global public health burden, driven largely by alcohol and drug dependence. According to the World Health Organization, approximately 400 million people worldwide live with alcohol use disorders, including nearly 209 million individuals with alcohol dependence, representing severe SUD cases. Drug use disorders affecting substances such as cannabis and opioids impact tens of millions globally. Epidemiological trends show the highest incidence among young adults aged 20-39 years, while men consistently demonstrate higher prevalence and mortality rates, although the prevalence among women has been gradually increasing across several substance categories.
Substance Use Disorder (SUD) – Pipeline Therapeutic Assessment
This section of the report covers the analysis of substance use disorder (SUD) drug candidates based on several segmentations, including:
By Phase
The pipeline assessment report covers 50+ drug analyses based on phase:
- Late-Stage Products (Phase 3 and Phase 4)
- Mid-Stage Products (Phase 2)
- Early-Stage Products (Phase I)
- Preclinical and Discovery Stage Products
By Drug Class
The substance use disorder (SUD) pipeline analysis report covers 50+ drug analyses based on drug classes:
- Small Molecules
- Monoclonal Antibodies
- Peptides
By Route of Administration
The pipeline assessment report covers 50+ drug analyses based on the route of administration:
- Oral
- Parenteral
- Others
Substance Use Disorder (SUD) Pipeline Assessment Segmentation, By Phases
The report covers phase I, phase II, phase III, phase IV, and early-phase drugs. The coverage includes an in-depth analysis of each drug across these phases. According to EMR analysis, covers a major share of the total substance use disorder (SUD) clinical trials. Early phase I accounts for 8%, phase I 20%, phase II 49%, phase III 14%, and phase IV 9% of trials. According to EMR analysis, phase II dominates the clinical pipeline.
Substance Use Disorder (SUD) Pipeline Assessment Segmentation, By Drug Classes
The drug molecule categories covered under the substance use disorder (SUD) pipeline analysis include small molecules, monoclonal antibodies, and peptides. The substance use disorder (SUD) report provides a comparative analysis of the drug classes for each drug in various phases of clinical trials for substance use disorder (SUD). For instance, in May 2023, the United States Food and Drug Administration approved Brixadi (buprenorphine extended-release injection) for the treatment of moderate to severe opioid use disorder. The therapy provides weekly or monthly subcutaneous dosing to reduce opioid cravings and withdrawal symptoms. The long-acting formulation is designed to improve treatment adherence and expand medication-assisted treatment options for patients with opioid dependence.
Substance Use Disorder (SUD) Clinical Trials – Key Players
The EMR report for the substance use disorder (SUD) pipeline covers the profile of key companies involved in clinical trials and their drugs under development. It provides a detailed substance use disorder (SUD) therapeutic assessment, analyzing the competitive dynamics of the clinical trial landscape. Below is the list of a few players involved in substance use disorder (SUD) clinical trials:
- Afasci Inc.
- Friends Research Institute, Inc.
- Pop Test Oncology LLC
- Eli Lilly and Company
- Boehringer Ingelheim
- Imbrium Therapeutics
- Altimmune, Inc.
- Antidote Therapeutics, Inc.
- Revive Therapeutics, Ltd.
- Alkermes, Inc.
- ViiV Healthcare
Substance Use Disorder (SUD) – Emerging Drugs Profile
This section covers the detailed analysis of each drug under multiple phases, including phase I, phase II, phase III, phase IV, and emerging drugs for substance use disorder (SUD). It includes product description, trial ID, study type, drug class, mode of administration, and recruitment status of substance use disorder (SUD) drug candidates.
Drug: XR-B|Drug: XR-NTX
XR-B and XR-NTX, sponsored by the Friends Research Institute, Inc., are extended-release formulations of buprenorphine and naltrexone being investigated for the treatment of substance use disorder, specifically opioid use disorder (OUD). These therapies belong to the opioid agonist and opioid antagonist drug classes, respectively. XR-B works by partially activating opioid receptors to reduce cravings and withdrawal symptoms, while XR-NTX blocks opioid receptors to prevent euphoric effects and relapse. The institute conducts clinical studies and collaborative research programs focused on improving evidence-based treatments for addiction and behavioral health disorders.
Drug: AFA-281
AFA-281, a small-molecule, orally administered dual inhibitor sponsored by Afasci Inc., is currently advancing through a Phase I clinical trial targeting Alcohol Use Disorder. The drug works by simultaneously inhibiting overactivated ion channels, normalizing neuronal excitability, and restoring nervous system function, while suppressing a pro-inflammatory enzyme to enhance the body's natural anti-inflammatory response. This randomized, double-blind, placebo-controlled crossover study is evaluating pharmacokinetic and pharmacodynamic interactions between AFA-281 and alcohol in healthy adult volunteers. The study is estimated to be completed by September 2029.
*Please note that this is only a partial list; the complete list of drugs will be available in the full report.*
Key Questions Answered in the Substance Use Disorder (SUD) Pipeline Insight Report
- Which companies/institutions are leading the substance use disorder (SUD) drug development?
- Which company is leading the substance use disorder (SUD) pipeline development activities?
- What is the current substance use disorder (SUD) commercial assessment?
- What are the opportunities and challenges present in the substance use disorder (SUD) pipeline landscape?
- What is the efficacy and safety profile of substance use disorder (SUD) pipeline drugs?
- Which company is conducting major trials for substance use disorder (SUD) drugs?
- Which companies/institutions are involved in substance use disorder (SUD) collaborations aimed at providing enhanced therapeutic alternatives for patients?
- What are the geographies covered for clinical trials in substance use disorder (SUD)?
Reasons To Buy This Report
The Substance Use Disorder (SUD) Pipeline Analysis Report provides a strategic overview of the latest and future landscape of treatments for substance use disorder (SUD). It provides necessary information for making informed investment decisions along with research, development, and strategic planning efforts. The stakeholders will benefit from the essential insights into substance use disorder (SUD) collaborations, regulatory environments, and potential growth opportunities.
Related Reports
Pricing Plans
Upto 15% Off
USD
-
$1999 $1799
-
$3099 $2789
-
$4599 $3909
-
$5999 $5099
*While we strive to always give you current and accurate information, the numbers depicted on the website are indicative and may differ from the actual numbers in the main report. At Expert Market Research, we aim to bring you the latest insights and trends in the market. Using our analyses and forecasts, stakeholders can understand the market dynamics, navigate challenges, and capitalize on opportunities to make data-driven strategic decisions.*
Looking for specific insights?
Get in touch with us for a customized solution tailored to your unique requirements and save upto 35%!
Report Summary
Explore our key highlights of the report and gain a concise overview of key findings, trends, and actionable insights that will empower your strategic decisions.
|
Scope of the Report |
Details |
|
Drug Pipeline by Clinical Trial Phase |
|
|
Route of Administration |
|
|
Drug Classes |
|
|
Leading Sponsors Covered |
|
|
Geographies Covered |
|
Mini Report
One User
USD 1,999
USD 1,799
tax inclusive*
- Selected Segments
- Printing Restrictions
- Excel Spreadsheet Delivered via Email
- Full Report
- Periodic Updates
- Post Sales Analysts Support
- Unlimited Prints
Single User License
One User
USD 3,099
USD 2,789
tax inclusive*
- All Segments
- Printing Restrictions
- PDF Delivered via Email
- Custom Report Layout
- Post Sales Analysts Support
- Periodic Updates
- Unlimited Prints
Five User License
Five User
USD 4,599
USD 3,909
tax inclusive*
- All Segments
- Five Prints Available
- PDF Delivered via Email
- Limited Free Customization
- Post Sales Analyst Support
- Custom Report Layout
- Periodic Updates
- Unlimited Prints
Corporate License
Unlimited Users
USD 5,999
USD 5,099
tax inclusive*
- All Segments
- Unlimited Prints Available
- PDF & Excel Delivery via Email
- Limited Free Customization
- Post Sales Analysts Support
- Discount On Next Update
- Custom Report Layout
*Please note that the prices mentioned below are starting prices for each bundle type. Kindly contact our team for further details.*
Bundle Type
Flash Bundle
20% OFF
Number of Reports: 3
Small Business Bundle
25% OFF
Number of Reports: 5
Growth Bundle
30% OFF
Number of Reports: 8
Enterprise Bundle
35% OFF
Number of Reports: 10
Overview
- Life Time Access
- Analyst Support Related to Report
- PDF Version of the Report
- Complimentary Excel Data Set
- Free Analyst Hours
- Complimentary Free 1 Month Subscription to Trade Data Base
- Complimentary One Month Subscription to Price Database (Chemicals only)
- Complimentary PPT Version of the Report
- Complimentary License Upgrade
- Complimentary Power BI Dashboards
- Life Time Access
- Analyst Support Related to Report
- PDF Version of the Report
- Complimentary Excel Data Set
- Free Analyst Hours - 50 Hours
- Complimentary Free 1 Month Subscription to Trade Data Base
- Complimentary One Month Subscription to Price Database (Chemicals only)
- Complimentary PPT Version of the Report
- Complimentary License Upgrade
- Complimentary Power BI Dashboards
- Life Time Access
- Analyst Support Related to Report
- PDF Version of the Report
- Complimentary Excel Data Set
- Free Analyst Hours - 80 Hours
- Complimentary Free 1 Month Subscription to Trade Data Base
- Complimentary One Month Subscription to Price Database (Chemicals only)
- Complimentary PPT Version of the Report
- Complimentary License Upgrade
- Complimentary Power BI Dashboards
- Life Time Access
- Analyst Support Related to Report
- PDF Version of the Report
- Complimentary Excel Data Set
- Free Analyst Hours - 100 Hours
- Complimentary Free 1 Month Subscription to Trade Data Base
- Complimentary One Month Subscription to Price Database (Chemicals only)
- Complimentary PPT Version of the Report
- Complimentary License Upgrade
- Complimentary Power BI Dashboards
*Please note that the prices mentioned below are starting prices for each bundle type. Kindly contact our team for further details.*
Flash Bundle
Number of Reports: 3
20%
tax inclusive*
- 3 Reports Included
- Life Time Acess
- Analyst Support Related to Report
- PDF Version of the Report
- Free 1 Month Subscription to Trade Data Base
- 1 Month Subscription to Price Database (Chemicals only)
- Complimentary Excel Data Set
- PPT Version of the Report
- Power BI Dashboards
- License Upgrade
- Free Analyst Hours
Small Business Bundle
Number of Reports: 5
25%
tax inclusive*
- 5 Reports Included
- Life Time Acess
- Analyst Support Related to Report
- PDF Version of the Report
- Complimentary Excel Data Set
- Free Analyst Hours - 50 Hours
- Free 1 Month Subscription to Trade Data Base
- 1 Month Subscription to Price Database (Chemicals only)
- Complimentary Excel Data Set
- PPT Version of the Report
- Power BI Dashboards
- License Upgrade
Growth Bundle
Number of Reports: 8
30%
tax inclusive*
- 8 Reports Included
- Life Time Acess
- Analyst Support Related to Report
- PDF Version of the Report
- Complimentary Excel Data Set
- Free Analyst Hours - 50 Hours
- Free 1 Month Subscription to Trade Data Base
- 1 Month Subscription to Price Database (Chemicals only)
- License Upgrade
- Free Analyst Hours - 80 Hours
- Power BI Dashboards
Enterprise Bundle
Number of Reports: 10
35%
tax inclusive*
- 10 Reports Included
- Life Time Acess
- Analyst Support Related to Report
- PDF Version of the Report
- Complimentary Excel Data Set
- Free Analyst Hours - 50 Hours
- Free 1 Month Subscription to Trade Data Base
- 1 Month Subscription to Price Database (Chemicals only)
- License Upgrade
- Power BI Dashboards
- Free Analyst Hours - 100 Hours
How To Order
Select License Type
Choose the right license for your needs and access rights.
Click on ‘Buy Now’
Add the report to your cart with one click and proceed to register.
Select Mode of Payment
Choose a payment option for a secure checkout. You will be redirected accordingly.
Strategic Solutions for Informed Decision-Making
Gain insights to stay ahead and seize opportunities.
Get insights & trends for a competitive edge.
Track prices with detailed trend reports.
Analyse trade data for supply chain insights.
Leverage cost reports for smart savings
Enhance supply chain with partnerships.
Connect For More Information
Our expert team of analysts will offer full support and resolve any queries regarding the report, before and after the purchase.
Our expert team of analysts will offer full support and resolve any queries regarding the report, before and after the purchase.
We employ meticulous research methods, blending advanced analytics and expert insights to deliver accurate, actionable industry intelligence, staying ahead of competitors.
Our skilled analysts offer unparalleled competitive advantage with detailed insights on current and emerging markets, ensuring your strategic edge.
We offer an in-depth yet simplified presentation of industry insights and analysis to meet your specific requirements effectively.
Share